The Application of HCG in Luteal Support for Frozen Embryo Transfer in Ovulation Cycle of Obese Women

What Was Tested

This registered not phased trial tested hCG (human chorionic gonadotropin).

It had two arms (groups): HCG in the luteal support of frozen embryo transfer during ovulation cycles in overweight women (experimental) and Overweight women who received regular progesterone supplementation during the ovulation cycle (placebo comparator).

As the control group, the pregnancy outcomes of overweight and obese women who received regular progesterone supplementation during the ovulation cycle were observed.

The registry classes the interventions as drug.

More on the Plan

In ART, due to ovulation induction and the particularity of the population, luteal phase deficiency usually exists, and in clinical practice, luteal phase support is routinely strengthened.

Progesterone is commonly used for luteal support in clinical practice.

According to the Chinese expert consensus on luteal support, HCG can be used for luteal support in the absence of OHSS.

Who Took Part

Enrollment: 750 planned participants were the target.

It was open to women only aged from 22 years up to 37 years.

Healthy volunteers could join, not only people with the condition.

The full record lists 1 inclusion and 3 exclusion criteria; among the exclusions: there is a history of adenomyosis, hydrosalpinx, intrauterine adhesions or untreated submucosal fibroids of the uterus.

How the Study Was Run

Design: randomized, parallel-group and single-blind.

The participants were allocated by chance, so the hCG (human chorionic gonadotropin) group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

In this single-blind hCG (human chorionic gonadotropin) study one party knew the assignments and the other did not.

Those kept unaware of assignments: participant.

It started in 2026-07-01 with completion listed for 2027-12-31.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Live birth (time frame: Pregnancy at 28 weeks or more).

It also tracked 1 secondary outcome, for example Pregnancy outcome.

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of hCG (human chorionic gonadotropin) in 750 people.

With 750 participants it is a large trial for this field.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the hCG (human chorionic gonadotropin) compound page, all human trials.